维普期刊资源整合服务平台（V6.5）

295篇 您的检索式：作者名="Lau GK"

选中清除导出查看参考文献查看引证文献引用追踪共15页首页上一页第1页下一页末页 /15 跳转

	题名	作者	年代	出处	被引量
1	A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation显示文摘	Hui CK Lie A Au WY Leung YH Ma SY Cheung WW Zhang HY Chim CS Kwong YL Liang R Lau GK	2006	中国生物学文摘2006，20，5：	10
2	Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa显示文摘	Buster EH Hansen BE Lau GK		Gastroenterology0，，：	2
3	Peginterferon alfa-2a.lamivudine,and the combination for HBeAg-positive chronic hepatitis B显示文摘	Lau GK Piratvisuth T Luo KX		0，，：	2
4	Use of immuomo dulatoly therapy (other than interferon)for the treatment of chromic hepatitis B virus infection显示文摘	Lau GK	2000	J Gastroenterol Hepatol2000，15，：	1
5	Guidelines for theassessment and management of non-alcoholic fatty liverdisease in the Asia-Pacific region : executive summary 显示文摘	FARRELL GC CHHTURI S LAU GK	2007	JGastroenterol Hepatol2007，22，：	1
6	Guidelines for the assess- ment and management of non - alcoholic fatty hver disease in the Asia - Pacific region : executive summary 显示文摘	Farsell GC Chitturi S Lau GK	2007	J Gastroenterol Hepatol2007，22，6：	1
7	Pegintederon alfa-2a alone,lamivudine alone,and the two incombination in patients with HBeAg-negative chronic hepatitisB显示文摘	Marcellin P Lau GK Bonino F		0，，：	1
8	Guidelines for the as- sessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region:executive summary 显示文摘	Farre11 GC Chitmri S Lau GK	2007	J Gastroen- terol Hepatol2007，22，6：	1
9	On-treatment monitor-ing of HBsAg levels to predict response to peginterferon alfa-2a in patients with HBeAg-positive chronic hepatitis显示文摘	Lau GK Marcellin P Brunetto M		0，，：	1
10	Thymosin-alpha 1 and famcidovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase显示文摘	LAU GK NANJI A HOU J el al	2002	J Viral Hepat2002，9，4：	1
11	Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B显示文摘	Lau GK Piratvisuth T Luo KX	2005	N Engl J Med2005，352，26：	1
12	Arginine reverses ethanol-induced inflammatory and fibrotic changes in liver despite continued ethanol administration显示文摘	Nanji AA Jokelainen K Lau GK	2001	Pharmacol Exp Ther2001，299，：	1
13	Guidelines for the assessment and management of nonalcoholic fatty liver disease in the Asia Pa- cific region executive summary 显示文摘	Farrell GC Chittri S Lau GK	2007	Gastroenterol Hepatl2007，22，6：	1
14	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update显示文摘	Sarin SK Kumar M Lau GK	2016	Hepatol /at2016，10，1：	1
15	High hepatitis B virus(HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietie cell transplantation 显示文摘	LAU GK LEUNG YH FONG DY	2002	Blood2002，99，7：	1
16	HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a forHBeAg-positive chronic hepatitis B 显示文摘	Fried MW Piratvisuth T Lau GK Marcellin P Chow WC Cooksley G Luo KX Paik SW Liaw YF Button P Popescu M	2008	Hepatology2008，47，2：	1
17	Peginterferon a-2a alone, lamivudinc alone, and the two in combination in patients with HBeAg negative chronic hepatitis B 显示文摘	Marcellin P Lau GK Bonino F	2004	N Engl J Med2004，351，12：	1
18	Use of immunomodulatory therapy ( other than interferon) for the treatment of chronic hepati is B virus infection显示文摘	Lau GK	2000	J Gastroen- terol Hepatol2000，15，1：	1
19	Does treatment with interferon-based therapy improve the natural history of chronic hepatitis B infection显示文摘	Lau GK	2007	J Hepatol2007，46，1：	1
20	Use of immunomodulatory therapy (other than interferon) for the treatment of chronic hepatitis B virus infection 显示文摘	GK	2000	J Gastroenterol Hepatol2000，，：	1

返回顶部每页显示：

共15页首页上一页第1页下一页末页 /15 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示